Life Sciences Ontario Fortifies Board to Drive Innovation Across Ontario's Life Sciences

TORONTO, ON – April 07, 2026 – Life Sciences Ontario (LSO) has significantly bolstered its leadership with the appointment of four highly influential leaders to its Board of Directors, a move that signals a strategic push to unify and advance the province's diverse life sciences ecosystem. The new members, announced following the organization's Annual General Meeting on March 25, 2026, bring a wealth of experience from critical, high-growth sectors including medical technology, agri-tech, pharmaceuticals, and nuclear medicine.

The newly appointed directors are Amelia Swanson, vice-president at Medtech Canada; Dave Smardon, president and CEO of Bioenterprise Canada; Leslie Madden, senior director and head of government affairs and policy at Moderna Canada; and Melody Greaves, executive director and vice-president of government relations at the Canadian Nuclear Isotope Council.

The appointments come at a pivotal time for Ontario's life sciences sector, which contributes over $58 billion to the provincial GDP but faces persistent challenges in seed-stage funding and global commercialization. The diverse expertise of the new board members appears tailor-made to address these issues and capitalize on the Ontario government's ambitious growth strategy for the sector.

“We are delighted to welcome such highly qualified professionals to the Board,” said Dr. Jason Field, president and CEO of Life Sciences Ontario, in a statement. “They each bring exceptional experience and a demonstrated ability to drive innovation, shape policy, and build meaningful partnerships. We look forward to working together to advance Ontario’s life sciences sector and strengthen its global competitiveness.”

Beyond Pharma: A Board Reflecting a Broader Ecosystem

The composition of the new board members underscores a significant trend: the broadening definition of "life sciences" beyond traditional pharmaceuticals. The inclusion of leaders from agri-tech and nuclear medicine signals LSO's commitment to fostering a more integrated bio-economy.

Dave Smardon's appointment brings deep expertise in an area of increasing importance. As the head of Bioenterprise Canada, he has been instrumental in building Canada’s Food & Agri-Tech Engine, a national accelerator that supports innovation at the intersection of agriculture, food, and technology. His background in venture capital and corporate leadership, combined with his advocacy for a united agricultural ecosystem, provides LSO with a crucial perspective on sustainable technology, food security, and the bio-economy—all vital components of a modern life sciences strategy.

Similarly, the addition of Melody Greaves from the Canadian Nuclear Isotope Council (CNIC) highlights the strategic importance of nuclear medicine. Ontario is a global leader in the production of medical isotopes, which are essential for advanced cancer therapies and diagnostic imaging. Greaves has been at the forefront of advocating for policies to maintain and grow this leadership, notably through the CNIC's "Isotopes for Hope" campaign, which aims to double Canada's production by 2030. Her expertise will be invaluable as LSO works to support this high-value sector and its role in cutting-edge healthcare.

Strengthening Advocacy with Policy Powerhouses

A common thread among the new appointees is their extensive experience in government relations and policy advocacy, creating a formidable team to navigate the complex regulatory and political landscapes of healthcare and innovation. This collective expertise directly addresses one of LSO’s core mandates: to influence policy and create a more favorable business environment.

Amelia Swanson of Medtech Canada is a veteran in this arena, with over two decades of experience across government, non-profit, and industry sectors. Her work involves building alliances to ensure patient access to medical technologies, a critical component of the healthcare system. Her prior roles within the Ontario government, including as director of operations to the minister of health, give her an insider's understanding of how to effectively shape public policy and drive legislative priorities.

Leslie Madden brings the perspective of a global biopharmaceutical innovator. As one of Moderna Canada's first employees, she played a key role in the company's regulatory strategy during the COVID-19 pandemic and is now leading its government affairs and policy efforts. Her experience navigating the complex pathways for bringing cutting-edge mRNA technologies to market in Canada provides LSO with critical insight into the needs of the pharmaceutical and biomanufacturing sectors, particularly in areas of pandemic preparedness and rare disease therapies.

Together with Greaves's advocacy work in the specialized field of nuclear isotopes, this trio of policy experts equips LSO with enhanced capabilities to tackle long-standing industry challenges. These include advocating for reforms to the Patented Medicine Prices Review Board (PMPRB), promoting value-based procurement models in the health system, and championing solutions to the critical seed-stage funding gap that LSO has identified as a major barrier to growth for early-stage companies.

Aligning with a Vision for Global Leadership

These strategic appointments align seamlessly with the Ontario government’s "Taking Life Sciences to the Next Level" strategy. Following an initial phase focused on biomanufacturing, the government recently unveiled Phase 2, committing an additional $146 million to advance research, unlock capital, and support the broader ecosystem. Initiatives include a new $24 million Life Sciences Scale-Up Fund and a $15 million program to address the shortage of wet lab space for startups.

The new LSO board is now perfectly positioned to help the sector capitalize on these government investments. The members' combined experience spans the entire innovation pipeline, from the early-stage startups Smardon supports to the global-scale commercialization Madden represents. This comprehensive view will enable LSO to provide more effective guidance on how public funds can be deployed to bridge the "funding desert" and help Ontario companies scale up within the province rather than moving to other jurisdictions.

By bringing together leaders from medtech, agri-tech, biopharma, and nuclear medicine, LSO is fostering the cross-sectoral collaboration needed to drive the next wave of innovation. The challenges facing healthcare and the economy are increasingly complex, requiring integrated solutions that draw on expertise from multiple fields. This new board composition reflects a forward-thinking vision for a resilient and interconnected life sciences sector capable of competing on the global stage and delivering transformative benefits to both the economy and the health of Canadians.

The move reinforces LSO's role not just as a representative body, but as a proactive driver of strategy for one of Ontario’s most vital economic engines.